There is increasing evidence that GSTs, and GSTP1 in particular, play an important role in drug resistance in breast and other cancers, and therefore, accurate and reliable assays determining the promoter methylation of this gene might be of great clinical value for patient stratification prior to treatment decision, as well as for the early detection of neoplasms. The gene discussed is HPGDS; the disease is neoplasm.